TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Menstrual Bleeding Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Bleeding Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to detect presence of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of near death experience (NDE)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Brain Injury Coping Skills Questionnaire (BICS-Q)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Buss Perry Aggression Questionnaire (AQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Recidivism
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Systemic microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Plaque Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain visual analogue scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on the Relative-Reinforcing Value (RRV) of Food Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of mild cognitive impairment occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tolerance according to reactogenic thresholds for allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of reactions IgE mediated
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of reactions non IgE mediated
Endpoint domain: Adverse events/effects
Primary endpoint: Number of treatment adjustments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in LDL cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Network contact test uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual and semiquantitative assessment of organs and biodistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V02Max detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testing yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to clinic
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Linkage to ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour area under cover (AUC) glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Observed/Self-Reported Emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in hamstring flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of CESM and CE-MRI in diagnosing breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of solicited and unsolicited local and/or systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of AEs and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with AEs or SAEs as assessed by physical examination
Endpoint domain: Adverse events/effects
Primary endpoint: Variability of cardiovascular markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability of hemodynamics markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants With and Without Antibodies to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Participants Having at Least One RT-qPCR Proven Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Participants Hospitalised Due to COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Time to first post-operative analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICSI outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PrEP continuation: refills with 45 days of PrEP initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PEP initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting-state MRI and DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of LY3502970
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration (Tmax) of LY3502970
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General quality of life: Short-Form Health Survey (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General quality of life: European Quality of Life 5 Dimension
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scoliosis-specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Salt concentration taste threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of salt liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of salt intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single and Dual-Task Timed Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single and Dual-Task Tandem Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple Shoulder Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Composite of major bleeding or death during NICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Estimated Risk of Gastrointestinal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of serious adverse events related to the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scale during infusion, dwell, and drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basic life support level of knowledge and skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of self confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of 2nd stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary urgency incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with grade III/IV hemorrhage attributable to defibrotide
Endpoint domain: Adverse events/effects
Primary endpoint: TMS derived measure of cortical plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition Readiness Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinue treatment due to adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: fMRI based measures of altered neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pleasantness ratings for the different types of applied touch
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parental knowledge and beliefs about children's sleep
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean of primary headache frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor regression grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Participants with HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of Tobacco Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients dying from COVID-19 pneumonia/ARDS
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants that attain PSA nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications in twin pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral pulsatility measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak diastolic and systolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain intensity during the day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year Recurrence Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Postprandial Muscle Protein Synthetic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric mean titer (GMT) of influenza HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: All-cause mortality within three months
Endpoint domain: Mortality/survival
Primary endpoint: Evaluation of reperfusion failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Highest-tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of AT-100
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Grade 3-5 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Health related quality of life in patients with metastatic prostate cancer
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Activity Scale For Elderly
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Back-saver sit-and-reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of minutes of moderate intensity exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-tear rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patients who exceed 17 J/min of MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Related Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total amount of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall score remind ecological MAI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patient-related outcome measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in laryngeal imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceptual evaluation of voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acoustic voice analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aerodynamic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Cognitive Functions from Base on the Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on Cognitive Functions from Base on the Stroop Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on Cognitive Functions from Base on the Trail Making Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on Quality of Life from Base on the World Health Organization Quality-of-Life Scale Turkish version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-reported abstinence at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy at 6-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under curve for plasma glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants registered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of post-pancreatectomy acute pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Wound recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants that remained after the last data is completed at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: participant level of satisfaction assessed using the Client Satisfaction Questionnaire version 8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of first hospitalization or emergency department (ED) visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants with POAF - In-hospital
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with POAF - Early
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with POAF - Intermediate
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1C lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of satisfaction from Gaucher treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of 68Ga-LNC1007 Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Baseline Percent Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: performance of healthcare workers
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Seroconversion rate of Neutralizing and IgG antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 specific memory B and T cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total sum of used IV additional opioid analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prodromal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of frailty assessed by the Edmonton Frail Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of frailty assessed by the Clinical Frailty Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microplastic composition in maternal breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microplastic composition in maternal venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microplastic composition in infant stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst development rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delivery accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of injury
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive accuracy of the AI tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acute airway opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airflow during acute assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Clinical Outcome (Hip and Knee)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Clinical Outcome (Shoulder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual appearance of target lesion to cranial blood pool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical respiratory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Amyloid beta 42:40 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurofilament light
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAE) in Part 1 (SAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant changes in blood pressure in Part 1 (SAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with clinically significant changes in heart rate in Part 1 (SAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin sensitivity during an oral glucose tolerance test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ferritin blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Turnover rate of endogenous and exogenous glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total walking distance at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Dengue IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of neutralizing antibodies against DENV1, DENV2, DENV3 and/or DENV4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with monotypic and multitypic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eligibility criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Ichthyosis Area Severity Index (IASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change from baseline in systolic arterial pressure after premedication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in diastolic arterial pressure after premedication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in heart rate after premedication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinician acceptance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient acceptance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Compliance with allocated intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PSMA-tracer accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUV > 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of finding a compatible donor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nail-phalange distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anastomotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of participants with eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes